Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression.

ABSTRACT:

Background

The relationship between proton-pump inhibitor (PPI) use and chronic kidney disease (CKD) progression remains controversial. Specifically, there is a lack of data evaluating renal outcomes in established CKD patients. The aim of our study is to determine the risk of progression to end-stage kidney disease (ESKD) or death amongst CKD patients on PPI, histamine-2 receptor blocker (H2B), or no anti-acid therapy.

Methods

Using our CKD registry, we evaluated the relationship between PPI and H2B use and outcomes amongst patients with CKD (eGFR < 60), with at least 2 PCP visits in the year prior. A Cox proportional hazards model was used to evaluate the relationship between medication groups and overall mortality, while competing risks regression models were used to dete

SUBMITTER: Cholin L 

PROVIDER: S-EPMC8281649 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature